SITC is pleased to announce the publication of a new manuscript titled “A SITC Strategic Vision: Prevention, Premalignant Immunity, Host and Environmental Factors,” available now in the Journal for ImmunoTherapy of Cancer (JITC).
This manuscript is the third in a JITC Special Series — The Next Wave of Immuno-oncology: A Roadmap from the Society for Immunotherapy of Cancer, which outlines the current state of the field, elevates the most pressing challenges, and proposes the most promising opportunities for high clinical impact in the scientific, clinical, and regulatory arenas of cancer immunotherapy. This series will serve as an update to the landmark editorial published by SITC leaders in 2011, “Defining the critical hurdles in cancer immunotherapy.”
In the 13 years since that publication, cancer immunotherapy has grown exponentially and completely transformed cancer care. As we enter the next era of cancer immunotherapy, SITC leadership recognized the importance of understanding the complex and evolving landscape of both old and new challenges that might hinder the next wave of immuno-oncology approvals or further progress in the field. To support and galvanize the field, an international, multidisciplinary group of cancer immunotherapy experts from academic, pharmaceutical, biotechnology, patient advocacy, and regulatory institutions was convened to redefine the most pressing challenges today and high-impact opportunities to overcome them.
Areas of Opportunity in Cancer Immunotherapy
This third manuscript in the series is an in-depth follow up to the manuscripts on pre-malignant immunity, immune interception, immunoprevention, and the impact of the host and environmental factors on responding to immunotherapy.
The groundbreaking advancements in the understanding of premalignant immunity and immune changes offers an incredible opportunity for leveraging the immune system to prevent cancer. Meanwhile, as the influence of host genomics and environmental factors are better appreciated, new opportunities are on the horizon to understand and influence immune response to therapy.
More information on the first manuscript and this special series can be found here.
